Protalix BioTherapeutics names Gilad Mamlok as new CFO

Protalix BioTherapeutics Inc. (NYSE American: PLX) announced the appointment of Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025.

Mamlok will succeed Eyal Rubin, who has served as CFO for six years. To ensure a transition, Mamlok has joined the company and is working alongside Rubin. After stepping down from the CFO role, Rubin will remain available to the company through October 2025.

The Israel-based biopharmaceutical company stated that Mamlok brings three decades of experience in healthcare and technology companies. He previously served as CFO of TytoCare Ltd., a privately-held remote healthcare company, and Sol-Gel Technologies Ltd., where he managed an initial public offering and other capital markets transactions.

Before his role at Sol-Gel, Mamlok worked at medical device companies including Given Imaging, which Covidien plc acquired in 2014. He holds a BA in Economics and a Master's degree in Business/Managerial Economics from Tel Aviv University.

"With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy," said Dror Bashan, Protalix's President and Chief Executive Officer.

Protalix develops recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company has licensed worldwide development and commercialization rights for taliglucerase alfa to Pfizer Inc. for Gaucher disease treatment, excluding Brazil where Protalix retains full rights.

The company's second product, Elfabrio, received approval from both the FDA and European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for global development and commercialization of Elfabrio.

You May Also Be Interested In

• Scribe Therapeutics files for proposed Nasdaq IPO
• Coty's chief people officer to resign in August
• Jersey Mike’s Subs files for IPO, set for public market debut